A recent study published in Alzheimer's & Dementia suggests that semaglutide, the weight-loss drug behind Ozempic and Wegovy, is associated with a lower predicted risk of dementia. This finding adds to growing evidence exploring whether GLP-1 receptor agonists may offer neuroprotective benefits beyond their metabolic effects.
Background
Semaglutide is a GLP-1 receptor agonist originally developed for type 2 diabetes and now widely prescribed for weight management. Previous research has hinted at potential cognitive benefits of GLP-1 drugs, making this area an active field of investigation.
- Source
- hackernews
- Published
- Aug 15, 2026 at 11:58 PM
- Score
- 7.0 / 10